These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 11591843

  • 1. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
    Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.
    Neurology; 2001 Oct 09; 57(7):1239-47. PubMed ID: 11591843
    [Abstract] [Full Text] [Related]

  • 2. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R, Zorzon M, De Masi R, Nasuelli D, Cazzato G.
    J Neurol Sci; 2008 Apr 15; 267(1-2):28-35. PubMed ID: 17945260
    [Abstract] [Full Text] [Related]

  • 3. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Apr 15; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 4. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.
    Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, Frank JA.
    Neurology; 2002 Sep 10; 59(5):688-94. PubMed ID: 12221158
    [Abstract] [Full Text] [Related]

  • 5. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
    Perumal JS, Caon C, Hreha S, Zabad R, Tselis A, Lisak R, Khan O.
    Eur J Neurol; 2008 Jul 10; 15(7):677-80. PubMed ID: 18459972
    [Abstract] [Full Text] [Related]

  • 6. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.
    BMC Neurol; 2006 May 23; 6():19. PubMed ID: 16719908
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
    Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW.
    Mult Scler; 2004 Feb 23; 10(1):89-91. PubMed ID: 14760960
    [Abstract] [Full Text] [Related]

  • 8. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
    Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
    [Abstract] [Full Text] [Related]

  • 9. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA, Fisher E, Lee JC, Duda JT, Simon J.
    Mult Scler; 2000 Dec 10; 6(6):365-72. PubMed ID: 11212130
    [Abstract] [Full Text] [Related]

  • 10. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
    Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió i Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J.
    Mult Scler; 2014 May 10; 20(6):717-25. PubMed ID: 24144876
    [Abstract] [Full Text] [Related]

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 10; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 12. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.
    Fox RJ, Fisher E, Tkach J, Lee JC, Cohen JA, Rudick RA.
    Mult Scler; 2005 Apr 10; 11(2):140-5. PubMed ID: 15794385
    [Abstract] [Full Text] [Related]

  • 13. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
    De Stefano N, Filippi M, Hawkins C, 9011 study group.
    J Neurol Sci; 2008 Mar 15; 266(1-2):44-50. PubMed ID: 17897678
    [Abstract] [Full Text] [Related]

  • 14. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
    Burton JM, O'Connor PW, Hohol M, Beyene J.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD006921. PubMed ID: 23235634
    [Abstract] [Full Text] [Related]

  • 15. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
    Lancet Neurol; 2010 Jul 12; 9(7):672-80. PubMed ID: 20542736
    [Abstract] [Full Text] [Related]

  • 16. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R, MN166-001 Investigators.
    Neurology; 2010 Mar 30; 74(13):1033-40. PubMed ID: 20200338
    [Abstract] [Full Text] [Related]

  • 17. Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    Di Gregorio M, Gaetani L, Eusebi P, Floridi P, Picchioni A, Rosi G, Mancini A, Floridi C, Baschieri F, Gentili L, Sarchielli P, Calabresi P, Di Filippo M.
    J Neurol; 2018 Mar 30; 265(3):522-529. PubMed ID: 29327284
    [Abstract] [Full Text] [Related]

  • 18. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
    Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Bergsland N, Vaneckova M, Zivadinov R.
    J Neurol Neurosurg Psychiatry; 2008 Apr 30; 79(4):407-14. PubMed ID: 17550987
    [Abstract] [Full Text] [Related]

  • 19. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.
    Mult Scler; 2002 Apr 30; 8(2):119-23. PubMed ID: 11990868
    [Abstract] [Full Text] [Related]

  • 20. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.
    Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA.
    Neurology; 2001 May 22; 56(10):1324-30. PubMed ID: 11376182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.